Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 7/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.51 |
| ▸ | RELA | Q04206 | 7/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207684 | 1.00 | NFKB1 (0.51) | NFKB1NFKB2RELASCN9ACCKAR | |
| SCHEMBL19207748 | 0.82 | MEN1 (0.43) | CCKBRKMT2AL3MBTL1 | |
| SCHEMBL11118972 | 0.82 | NFKB1 (0.46) | NFKB1NFKB2RELACCKARCCKBR | |
| SCHEMBL8903935 | 0.79 | SMN1; SMN2 (0.40) | KMT2AL3MBTL1 | |
| SCHEMBL7808673 | 0.75 | SCN9A (0.52) | NFKB1NFKB2RELASCN9ACCKAR | |
| SCHEMBL9040876 | 0.74 | SCN9A (0.44) | NFKB1NFKB2RELASCN9ACCKAR | |
| SCHEMBL28513980 | 0.74 | PSEN1 (0.46) | SCN9AKMT2AL3MBTL1 | |
| SCHEMBL9266788 | 0.74 | SCN9A (0.44) | NFKB1NFKB2RELASCN9ACCKAR | |
| SCHEMBL4799468 | 0.72 | SCN9A (0.56) | SCN9A | |
| SCHEMBL7423602 | 0.72 | SCN9A (0.56) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2019-04-18 | — | — | US | disclosed |
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-04-12 | — | — | US | disclosed |
| US-9896458-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896458-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | NFKB1 1232/4885NFKB2 1292/4885RELA 840/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | NFKB1 2747/4885NFKB2 2519/4885RELA 3626/4885 |
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | NFKB1 1232/4885NFKB2 1292/4885RELA 840/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | NFKB1 1232/4885NFKB2 1292/4885RELA 840/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | NFKB1 1232/4885NFKB2 1292/4885RELA 840/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | NFKB1 1232/4885NFKB2 1292/4885RELA 840/4885 |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | NFKB1 1232/4885NFKB2 1292/4885RELA 840/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | NFKB1 1232/4885NFKB2 1292/4885RELA 840/4885 |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | NFKB1 1232/4885NFKB2 1292/4885RELA 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.